Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7794-7803

  Gradishar, William J ^a   Tjulandin, Sergei ^b   Davidson, Neville ^b   Shaw, Heather ^b   Desai, Neil ^b   Bhar, Paul ^b   Hawkins, Michael ^b   O'Shaughnessy, Joyce ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GROWTH FACTOR; NANOPARTICLE; PACLITAXEL; RICINOMACROGOL; ALBUMINOID; ANTINEOPLASTIC AGENT; CASTOR OIL; DRUG DERIVATIVE; NANOMATERIAL;

ADULT; AGED; ALLERGY; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; THORAX PAIN; TOXICITY; TREATMENT OUTCOME; TUMOR GROWTH; BREAST TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CASTOR OIL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NANOSTRUCTURES; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 32944482677     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.937     Document Type: Article

References (38)

1. Taxol (paclitaxel) Injection: Package Insert. Princeton, NJ, Bristol-Myers Squibb Co, 2003
2. Taxotere (docetaxel) Injection Concentrate: Package Insert. Bridgewater, NJ, Aventis Pharmaceutical Products, Inc, April 2003
3. Gelderblom H, Verweij J, Nooter K, et al: Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598, 2001
4. Lorenz W, Reimann HJ, Schmal A, et al: Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents Actions 7:63-67, 1977
5. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268, 1990
6. ten Tije AJ, Verweij J, Loos WJ, et al: Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685, 2003
7. Sparreboom A, van Zuylen L, Brouwer E, et al: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 59:1454-1457, 1999
8. Winer E, Berry D, Duggan D, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol 22:2061-2068, 2004
9. van Tellingen O, Huizing MT, Panday VR, et al: Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330-335, 1999
10. Desai N, Trieu V, Yao R, et al: Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol: Role of a novel albumin transporter mechanism. Presented at the 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003
11. Ibrahim NK, Desai N, Legha S, et al: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044, 2002
12. Nabholtz J-M, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. van Elteren PH: On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 37:351-361, 1960
16. Desai N, Yao Z, Trieu V, et al: Evidence of a novel transporter mechanism for a Cremophor-free, protein-engineered paclitaxel (ABI-007) and enhanced in vivo antitumor activity in an MX-1 human breast tumor xenograft model. Presented at the 25th Annual San Antonio Breast Conference Symposium, San Antonio, TX, December 11-14, 2002
17. van Zuylen L, Verweij J, Sparreboom A: Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125-141, 2001
18. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271:58-65, 1994
19. Knemeyer I, Wientjes MG, Au JLS: Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44:241-248, 1999
20. Kumar GN, Walle UK, Bhalla KN, et al: Binding of Taxol to human plasma, albumin and alpha1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80:337-344, 1993
21. Fang J, Sawa T, Maeda H: Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 519:29-49, 2003
22. John TA, Vogel SM, Tiruppathi C, et al: Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 284:L187-L196, 2003
23. Simionescu M, Gafencu A, Antohe F: Transcytosis of plasma macromolecules in endothelial cells: A cell biological survey. Microsc Res Tech 57:269-288, 2002
24. Schubert W, Frank PG, Razani B, et al: Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 276:48619-48622, 2001
25. Tahir SA, Ren C, Timme TL, et al: Development of an immunoassay for serum caveolin-1: A novel biomarker for prostate cancer. Clin Cancer Res 9:3653-3659, 2003
26. Desai N, Trieu V, Yao R, et al: Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: A pathway inhibited by Taxol. Presented at the 16th Annual Meeting of the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research, Geneva, Switzerland, September 28-October 1, 2004
27. Kim YW, Park Y, Lee J, et al: Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 13:652-657, 1998
28. Schiemann BJ, Neil JR, Schiemann WP: SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 14:3977-3988, 2003
29. Desai N, Trieu V, Yao R, et al: SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs Taxol. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004
30. Sparreboom A, Verweij J, van der Burg ME, et al: Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937-1942, 1998
31. Ravdin P, Erban J, Overmoyer B, et al: Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur J Cancer 1:S201, 2003 (suppl)
32. Authier N, Gillet JP, Fialip J, et al: Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 887:239-249, 2000
33. Postma TJ, Vermorken JB, Liefting AJM, et al: Paclitaxel-induced neuropathy. Ann Oncol 6:489-494, 1995
34. Tabernero J, Climent MA, Lluch A, et al: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365, 2004
35. Sahenk Z, Barohn R, New P, et al: Taxol neuropathy. Arch Neurol 51:726-729, 1994
36. Rowinsky EK, Chaudhry V, Cornblath DR, et al: Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 15:107-115, 1993
37. Bissery M-C: Preclinical pharmacology of docetaxel. Eur J Cancer 31A:S1-S6, 1995 (suppl 4)
38. Blum JL, Savin MA, Edelman G, et al: Long-term disease control in taxane-refractory metastatic breast cancer treated with nab-paclitaxel. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004